Khiron Life Sciences Corp. Launch event

Lanzamiento Khiron

December 7 of 2017

Khiron Life Sciences Corp. Launch event

 

Khiron Life Sciences Corp. is a Canadian vertically integrated company of medicinal cannabis with core operations in Colombia. Khiron combines leading international scientific expertise, agricultural advantages, branded product development and market entrance experience to address the unmet medical needs in a market of over 620 million people in Latin America.

 

In 2017, Colombia took an important step on legalizing cannabis products for medicinal purposes, which will translate into benefits in the quality of life of patients with diverse medical conditions such as chronic pain, epilepsy, multiple sclerosis, nausea caused by chemotherapy, among others. For this reason, Khiron has focused its efforts on being one of the first companies to obtain licenses in the country to cultivate, produce and distribute medicinal cannabis.


 
On December 6, 2017, Khiron sponsored its launch event at the JW Marriot Hotel in Bogotá. The event was attended by investors and people from the health sector, medical associations, patient representatives, regulatory authorities and government, financial and communication entities, among others; who knew firsthand how Khiron prepares to meet the needs of about 5 million patients in the country and 64 million in Latin America.

 

With the testimonies of Dr. Sergio Ramírez (president of the Colombian Association of Neurology), Andres López (director of the National Narcotics Fund) and Matthew Murphy (Chief Compliance Officer at Khiron); the attendees had the opportunity to understand the point of view these key opinion leaders regarding the benefits that companies like Khiron generate by entering the market.

 

Khiron's reason for being is the patients well-being, that’s why it is worth highlighting the participation in the forum of people who shared their experience about medicinal cannabis and the benefits it has generated for themselves and their families.


From the regulatory and medical point of view, Juan Diego Álvarez, considered one of the most knowledgeable about the regulation of medicinal cannabis in Colombia and Chief Regulatory Officer at Khiron; and Dr. Paulo Vega, neurologist with more than 25 years of experience and Chief Medical Officer at Khiron; contributed their opinion as specialists in the national reality both from the regulatory perspective and from the health problems that most afflict Colombians.

 

In 2018, Khiron will be the first Colombian-Canadian medicinal cannabis company to go on the Toronto Stock Exchange (TSX: V) and will focus its efforts on its continuing education plan to the medical community, in order to continue giving information to doctors about the benefits of medicinal cannabis to improve the quality of life of patients and their families.

 

Álvaro Torres, CEO of Khiron, explains why education is a fundamental pillar in this equation: "We believe that our scientific approach and our patient-centered strategy will make us a first-rate player in the country, and in the medium term in Latin America , but we also encourage initiatives that help strengthen the industry and protect it in the long term. "

Switch Language